Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)

Janet Chou, Craig D Platt, Saddiq Habiballah, Alan A Nguyen, Megan Elkins, Sabrina Weeks, Zachary Peters, Megan Day-Lewis, Tanya Novak, Myriam Armant, Lucinda Williams, Shira Rockowitz, Piotr Sliz, David A Williams, Adrienne G Randolph, Raif S Geha, Taking on COVID-19 Together Study Investigators, Abduarahman Almutairi, Faris Jaber, Tina Banzon, Jordan Roberts, Olha Halyabar, Mindy Lo, Stacy Kahn, Lauren A Henderson, Pui Y Lee, Mary Beth Son, Leah Cheng, Janet Chou, Craig D Platt, Saddiq Habiballah, Alan A Nguyen, Megan Elkins, Sabrina Weeks, Zachary Peters, Megan Day-Lewis, Tanya Novak, Myriam Armant, Lucinda Williams, Shira Rockowitz, Piotr Sliz, David A Williams, Adrienne G Randolph, Raif S Geha, Taking on COVID-19 Together Study Investigators, Abduarahman Almutairi, Faris Jaber, Tina Banzon, Jordan Roberts, Olha Halyabar, Mindy Lo, Stacy Kahn, Lauren A Henderson, Pui Y Lee, Mary Beth Son, Leah Cheng

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) is a pediatric complication of severe acute respiratory syndrome coronavirus 2 infection that is characterized by multiorgan inflammation and frequently by cardiovascular dysfunction. It occurs predominantly in otherwise healthy children. We previously reported haploinsufficiency of suppressor of cytokine signaling 1 (SOCS1), a negative regulator of type I and II interferons, as a genetic risk factor for MIS-C.

Objectives: We aimed to identify additional genetic mechanisms underlying susceptibility to severe acute respiratory syndrome coronavirus 2-associated MIS-C.

Methods: In a single-center, prospective cohort study, whole exome sequencing was performed on patients with MIS-C. The impact of candidate variants was tested by using patients' PBMCs obtained at least 7 months after recovery.

Results: We enrolled 18 patients with MIS-C (median age = 8 years; interquartile range = 5-12.25 years), of whom 89% had no conditions other than obesity. In 2 boys with no significant infection history, we identified and validated hemizygous deleterious defects in XIAP, encoding X-linked inhibitor of apoptosis, and CYBB, encoding cytochrome b-245, beta subunit. Including the previously reported SOCS1 haploinsufficiency, a genetic diagnosis was identified in 3 of 18 patients (17%). In contrast to patients with mild COVID-19, patients with defects in SOCS1, XIAP, or CYBB exhibit an inflammatory immune cell transcriptome with enrichment of differentially expressed genes in pathways downstream of IL-18, oncostatin M, and nuclear factor κB, even after recovery.

Conclusions: Although inflammatory disorders are rare in the general population, our cohort of patients with MIS-C was enriched for monogenic susceptibility to inflammation. Our results support the use of next-generation sequencing in previously healthy children who develop MIS-C.

Keywords: COVID-19; MIS-C; Multisystem inflammatory syndrome in children; SARS-CoV-2; whole exome sequencing.

Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Fig 1
Fig 1
Genetic risk factors for MIS-C. A, Schematic of XIAP with structural modeling of the ubiquitin-associated (UBA) domain identifies a new hydrogen bond (indicated by the dotted red line) formed between the S421N mutant found in patient 1 and alanine 417. B, Flow cytometric quantification of XIAP protein expression in CD14+ monocytes from a control (Ctrl) and the patient from 2 experiments with 3 controls. C, Quantification of HLA-DR+TNF-α+ monocytes, gated on CD14+ cells, after stimulation with 200 ng/mL of muramyl dipeptide or LPS for 2.5 hours in 2 experiments with 5 controls. D, IL-1β secretion after stimulation of PBMCs from 4 controls and patient 1 with indicated stimuli, pooled from 2 experiments. E, TNF-α secretion after stimulation of PBMCs from 4 controls and patient 1, pooled from 2 experiments. F, Schematic of CYBB. G, Quantification of the neutrophil oxidative burst in the presence and absence of stimulation with phorbol 12–myristate 13–acetate, pooled from 3 independent experiments with 13 controls. max, Maximum; MFI, mean fluorescence intensity; n.s., not significant; NOI, neutrophil oxidative index; stim, stimulated; unstim, unstimulated.
Fig 2
Fig 2
A, Transcriptome analysis of unstimulated PBMCs from patients 1 and 2, as well as those from the patient with SOCS1 haploinsufficiency whom we previously described, compared with PBMCs from 4 otherwise healthy individuals who had previously had mild COVID-19. PBMCs were collected at least 7 months after recovery, at which time the individuals had returned to their baseline state of health. ∗P < .05; ∗∗P < .01 by the Mann-Whitney test. B, Uniform Manifold Approximation and Projection (UMAP) plots depict transcriptional clusters generated by single-cell RNA sequencing of PBMCs from a control and a patient with active MIS-C but no identifiable genetic diagnosis. This research sample was taken early in the patient’s course; she had received 1 dose of IVIG but subsequently required additional doses of IVIG and methylprednisolone before clinical improvement occurred. Ingenuity Pathway Analysis of differentially expressed genes indicates upregulation of signaling pathways downstream of type I and/or II interferons, STAT1, IRF3, and IRF7. mono, Monocyte; NF-κB, nuclear factor κB; NK, natural killer.

References

    1. Feldstein L.R., Rose E.B., Horwitz S.M., Collins J.P., Newhams M.M., Son M.B.F. Multisystem inflammatory syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383:334–346.
    1. Lee P.Y., Day-Lewis M., Henderson L.A., Friedman K.G., Lo J., Roberts J.E. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130:5942–5950.
    1. CDC . Centers for Disease Control and Prevention; 2020. Multisystem inflammatory syndrome in children (MIS-C) [Internet] Available at:
    1. Zhang Q., Bastard P., Liu Z., Pen J.L., Moncada-Velez M., Chen J. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 [abstract] Science. 2020;370
    1. van der Made C.I., Simons A., Schuurs-Hoeijmakers J., van den Heuvel G., Mantere T., Kersten S. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324:663.
    1. Lee P.Y., Platt C.D., Weeks S., Grace R.F., Maher G., Gauthier K. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020;146:1196–1200.
    1. Jost P.J., Vucic D. Regulation of cell death and immunity by XIAP. Cold Spring Harb Perspect Biol. 2020;12
    1. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116:1079–1082.
    1. Yabal M., Müller N., Adler H., Knies N., Groß C.J., Damgaard R.B. XIAP Restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep. 2014;7:1796–1808.
    1. Hsieh W.-C., Chuang Y.-T., Chiang I.-H., Hsu S.-C., Miaw S.-C., Lai M.-Z. Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice. Blood. 2014;124:2847–2857.
    1. Zhao Y., Kuang M., Li J., Zhu L., Jia Z., Guo X. SARS-CoV-2 spike protein interacts with and activates TLR4. Cell Res. 2021:1–3.
    1. Sweeny K.F., Zhang Y.J., Crume B., Martz C.A., Blessing M.M., Kahn S.A. Inflammatory bowel disease presenting with concurrent COVID-19 multisystem inflammatory syndrome. Pediatrics. 2021;147
    1. Meissner F., Seger R.A., Moshous D., Fischer A., Reichenbach J., Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood. 2010;116:1570–1573.
    1. Meda Spaccamela V., Valencia R.G., Pastukhov O., Duppenthaler A., Dettmer M.S., Erb J. High levels of IL-18 and IFN-γ in chronically inflamed tissue in chronic granulomatous disease. Front Immunol. 2019;10:2236.
    1. van de Geer A., Nieto-Patlán A., Kuhns D.B., Tool A.T.J., Arias A.A., Bouaziz M. Inherited p40phox deficiency differs from classic chronic granulomatous disease. J Clin Invest. 2018;128:3957–3975.
    1. Wada T., Kanegane H., Ohta K., Katoh F., Imamura T., Nakazawa Y. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65:74–78.
    1. Thaventhiran J.E.D., Lango Allen H., Burren O.S., Rae W., Greene D., Staples E. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020;583:90–95.
    1. Arunachalam P.S., Wimmers F., Mok C.K.P., Perera R.A.P.M., Scott M., Hagan T. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210–1220.
    1. Bai B., Yang Y., Wang Q., Li M., Tian C., Liu Y. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020;11:1–18.
    1. Pothlichet J., Meunier I., Davis B.K., Ting J.P.-Y., Skamene E., von Messling V. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog. 2013;9
    1. Meyts I., Bucciol G., Quinti I., Neven B., Fischer A., Seoane E. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2020;147:520–531.
    1. Sancho-Shimizu V., Brodin P., Cobat A., Biggs C.M., Toubiana J., Lucas C.L. SARS-CoV-2–related MIS-C: a key to the viral and genetic causes of Kawasaki disease [abstract]? J Exp Med [Internet] 2021;218
    1. Rockowitz S., LeCompte N., Carmack M., Quitadamo A., Wang L., Park M. Children’s rare disease cohorts: an integrative research and clinical genomics initiative. NPJ Genom Med. 2020;5:29.
    1. Genome Aggregation Database Consortium. Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alföldi J. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–443.
    1. Nakao A. RPG: the Ribosomal Protein Gene database. Nucleic Acids Res. 2004;32:168D–170D.
    1. Marsh R.A., Villanueva J., Zhang K., Snow A.L., Su H.C., Madden L. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009;76:334–344.
    1. Ammann S., Elling R., Gyrd-Hansen M., Dückers G., Bredius R., Burns S.O. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin Exp Immunol. 2014;176:394–400.
    1. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A. Gene Set Enrichment Analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545–15550.
    1. Mootha V.K., Lindgren C.M., Eriksson K.-F., Subramanian A., Sihag S., Lehar J. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–273.

Source: PubMed

3
Abonnieren